IsorhynchophyllineCAS# 6859-1-4 |
- Corynoxine B
Catalog No.:BCN8454
CAS No.:17391-18-3
- Isorhyncophylline
Catalog No.:BCN3466
CAS No.:6859-01-4
- Corynoxine
Catalog No.:BCN2364
CAS No.:6877-32-3
- Rhynchophylline
Catalog No.:BCN4979
CAS No.:76-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 6859-1-4 | SDF | Download SDF |
PubChem ID | 3037048 | Appearance | Powder |
Formula | C22H28N2O4 | M.Wt | 384.5 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Synonyms | Isorhyncophylline | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | methyl (E)-2-[(3S,6'R,7'S,8'aS)-6'-ethyl-2-oxospiro[1H-indole-3,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate | ||
SMILES | CCC1CN2CCC3(C2CC1C(=COC)C(=O)OC)C4=CC=CC=C4NC3=O | ||
Standard InChIKey | DAXYUDFNWXHGBE-VKCGGMIFSA-N | ||
Standard InChI | InChI=1S/C22H28N2O4/c1-4-14-12-24-10-9-22(17-7-5-6-8-18(17)23-21(22)26)19(24)11-15(14)16(13-27-2)20(25)28-3/h5-8,13-15,19H,4,9-12H2,1-3H3,(H,23,26)/b16-13+/t14-,15-,19-,22-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Isorhynchophylline exerts anticancer and anti-metastatic effects through regulation of multiple signaling cascades in hepatocellular carcinoma cells. 2. Isorhynchophylline exerts neuroprotective effect against Aβ 25-35-induced neurotoxicity in vitro via PI3K/Akt signaling pathway. 3. Isorhynchophylline shows antidepressant-like effects, which are mediated, at least in part, by the inhibition of monoamine oxidases. 4. Isorhynchophylline shows inhibition on angiotensin II-induced proliferation in rat vascular smooth muscle cells. 5. Isorhynchophylline shows anti-inflammatory effects in mouse N9 microglial cells. 6. Isorhynchophylline plays a remarkably preventive role in cardiac arrhythmias through the inhibition of calcium currents in rats and guinea pigs. |
Targets | PI3K | Akt | Beta Amyloid | p38MAPK | ERK | JNK | STAT | p53 | GSK-3 | NO | NOS |
Isorhynchophylline Dilution Calculator
Isorhynchophylline Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6008 mL | 13.0039 mL | 26.0078 mL | 52.0156 mL | 65.0195 mL |
5 mM | 0.5202 mL | 2.6008 mL | 5.2016 mL | 10.4031 mL | 13.0039 mL |
10 mM | 0.2601 mL | 1.3004 mL | 2.6008 mL | 5.2016 mL | 6.502 mL |
50 mM | 0.052 mL | 0.2601 mL | 0.5202 mL | 1.0403 mL | 1.3004 mL |
100 mM | 0.026 mL | 0.13 mL | 0.2601 mL | 0.5202 mL | 0.6502 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isorhyncophylline
Catalog No.:BCN3466
CAS No.:6859-01-4
- PX-478 2HCl
Catalog No.:BCC6502
CAS No.:685898-44-6
- Prometaphanine
Catalog No.:BCN4244
CAS No.:6858-85-1
- Moschamine
Catalog No.:BCN3900
CAS No.:68573-23-9
- Pridinol Methanesulfonate
Catalog No.:BCC3845
CAS No.:6856-31-1
- Eupatoriopicrin
Catalog No.:BCN7116
CAS No.:6856-01-5
- GSK 264220A
Catalog No.:BCC6062
CAS No.:685506-42-7
- Cilostamide
Catalog No.:BCC6843
CAS No.:68550-75-4
- Isoguvacine hydrochloride
Catalog No.:BCC6575
CAS No.:68547-97-7
- Angiotensin II
Catalog No.:BCC1030
CAS No.:68521-88-0
- Vigabatrin
Catalog No.:BCC2039
CAS No.:68506-86-5
- Pramiracetam
Catalog No.:BCC4928
CAS No.:68497-62-1
- Xylobiose
Catalog No.:BCN8424
CAS No.:6860-47-5
- Procerine
Catalog No.:BCN2017
CAS No.:68622-81-1
- Otenabant
Catalog No.:BCC1828
CAS No.:686344-29-6
- CP-945598 HCl
Catalog No.:BCC1082
CAS No.:686347-12-6
- BOP-Cl
Catalog No.:BCC2808
CAS No.:68641-49-6
- (±)-Palmitoylcarnitine chloride
Catalog No.:BCC6718
CAS No.:6865-14-1
- IWP-2
Catalog No.:BCC1665
CAS No.:686770-61-6
- BC 11-38
Catalog No.:BCC7940
CAS No.:686770-80-9
- IWP 4
Catalog No.:BCC5602
CAS No.:686772-17-8
- Qianhucoumarin G
Catalog No.:BCN3704
CAS No.:68692-61-5
- Retronecine N-oxide
Catalog No.:BCN2035
CAS No.:6870-33-3
- Jacobine
Catalog No.:BCN2087
CAS No.:6870-67-3
Antidepressant-Like Effect of Isorhynchophylline in Mice.[Pubmed:27900600]
Neurochem Res. 2017 Feb;42(2):678-685.
Isorhynchophylline (IRN), an oxindole alkaloid, has been identified as the main active ingredient responsible for the biological activities of Uncaria rhynchophylla (Miq) Miq ex Havil. (Rubiaceae). Previous studies in our laboratory have revealed that IRN possesses potent neuroprotective effects in different models of Alzheimer's disease. However, the antidepressant-like effects of IRN are remained unclear. The present study aims to evaluate the antidepressant-like effects of IRN. The antidepressant-like effects of IRN was determined by using animal models of depression including forced swimming and tail suspension tests. The acting mechanism was explored by determining the effect of IRN on the levels of monoamine neurotransmitters and the activities of monoamine oxidases. Intragastric administration of IRN at 10, 20 and 40 mg/kg for 7 days caused a significant reduction of immobility time in both forced swimming and tail suspension tests, while IRN did not stimulate locomotor activity in the open-field test. In addition, IRN treatment antagonized reserpine-induced ptosis and significantly enhanced the levels of monoamine neurotransmitters including norepinephrine (NE) and 5-hydroxytryptamine (5-HT), and the activity of monoamine oxidase A (MAO-A) in the hippocampus and frontal cortex of mice. These results suggest that the antidepressant-like effects of IRN are mediated, at least in part, by the inhibition of monoamine oxidases.
Effects of isorhynchophylline on angiotensin II-induced proliferation in rat vascular smooth muscle cells.[Pubmed:19000373]
J Pharm Pharmacol. 2008 Dec;60(12):1673-8.
Proliferation of vascular smooth muscle cells (VSMCs) is a crucial event in cardiovascular diseases. Isorhynchophylline, an alkaloid from a traditional Chinese medicine Gambirplant, has been used to treat cardiovascular diseases. The aim of this study was to investigate the effects of Isorhynchophylline on angiotensin II (Ang II)-induced proliferation of rat VSMCs. VSMCs were isolated from rat artery and cultured for 14 days before experimentation. The effect of Isorhynchophylline on Ang II-induced proliferation was evaluated by cell number, MTT assay and flow cytometry, and nitric oxide (NO) content and activity of NO synthase (NOS) were measured. The expression of proto-oncogene c-fos, osteopontin (OPN) and proliferating cell nuclear antigen (PCNA) mRNAs was measured by real-time RT-PCR. VSMC cultures were verified by morphology and immunostaining with alpha-smooth muscle actin. Isorhynchophylline (0.1-10.0 microM) was not toxic to VSMCs, but markedly decreased Ang II (1.0 microM)-enhanced cell number and MTT intensity, and blocked cell transition from G(0)/G(1) to S phase. Furthermore, Isorhynchophylline increased the NO content and NOS activity, and suppressed Ang II-induced over-expression of c-fos, OPN and PCNA. Thus, Isorhynchophylline was effective against Ang-II induced cell proliferation, an effect that appears to be due, at least in part, to increased NO production, regulation of the cell cycle, and depressed expression of c-fos, OPN and PCNA related to VMSC proliferation.
Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades.[Pubmed:28534824]
Int J Mol Sci. 2017 May 19;18(5). pii: ijms18051095.
Isorhynchophylline (Rhy) is an active pharmacological component of Uncaria rhynchophylla that has been reported previously to exert significant antihypertensive and neuroprotective effects. However, very little is known about its potential anti-cancer activities. This study was carried out to evaluate the anticancer effects of Rhy against various human carcinoma cell lines. We found that Rhy exhibited substantial cytotoxic effect against human hepatocellular carcinoma HepG2 cells when compared with other human carcinoma cell lines including those of lung, pancreas, prostate, head and neck, breast, multiple myeloma, brain and renal cell carcinoma. Rhy induced apoptosis as characterized by accumulation of cells in sub G1 phase; positive Annexin V binding; activation of caspase-8, -9, and -3; and cleavage of PARP (poly-ADP ribose polymerase). This effect of Rhy correlated with the down-regulation of various proteins that mediated cell proliferation, cell survival, metastasis, and angiogenesis. Moreover, cell proliferation, migration, and constitutive CXCR4 (C-X-C chemokine receptor type 4), MMP-9 (Matrix metallopeptidase-9), and MMP-2 expression were inhibited upon Rhy treatment. We further investigated the effect of Rhy on the oncogenic cell signaling cascades through phospho-kinase array profiling assay. Rhy was found to abrogate phospho-p38, ERK, JNK, CREB, c-Jun, Akt, and STAT3 signals, but interestingly enhanced phospho-p53 signal. Overall, our results indicate, for the first time, that Rhy could exert anticancer and anti-metastatic effects through regulation of multiple signaling cascades in hepatocellular carcinoma cells.
Protective effects of isorhynchophylline on cardiac arrhythmias in rats and guinea pigs.[Pubmed:21294075]
Planta Med. 2011 Sep;77(13):1477-81.
As one important constituent extracted from a traditional Chinese medicine, Uncaria Rhynchophylla Miq Jacks, Isorhynchophylline has been used to treat hypertension, epilepsy, headache, and other illnesses. Whether Isorhynchophylline protects hearts against cardiac arrhythmias is still incompletely investigated. This study was therefore aimed to examine the preventive effects of Isorhynchophylline on heart arrhythmias in guinea pigs and rats and then explore their electrophysiological mechanisms. In vivo, ouabain and calcium chloride were used to establish experimental arrhythmic models in guinea pigs and rats. In vitro, the whole-cell patch-lamp technique was used to study the effect of Isorhynchophylline on action potential duration and calcium channels in acutely isolated guinea pig and rat cardiomyocytes. The dose of ouabain required to induce cardiac arrhythmias was much larger in guinea pigs administered with Isorhynchophylline. Additionally, the onset time of cardiac arrhythmias induced by calcium chloride was prolonged, and the duration was shortened in rats pretreated with Isorhynchophylline. The further study showed that Isorhynchophylline could significantly decrease action potential duration and inhibit calcium currents in isolated guinea pig and rat cardiomyocytes in a dose-dependent manner. In summary, Isorhynchophylline played a remarkably preventive role in cardiac arrhythmias through the inhibition of calcium currents in rats and guinea pigs.
Anti-inflammatory effects of rhynchophylline and isorhynchophylline in mouse N9 microglial cells and the molecular mechanism.[Pubmed:19781666]
Int Immunopharmacol. 2009 Dec;9(13-14):1549-54.
Excessive production of nitric oxide (NO) and proinflammatory cytokines from activated microglia contributes to human neurodegenerative disorders. Our previous study demonstrated the potent inhibition of lipopolysaccharide (LPS)-induced NO production in rat primary microglial cells by rhynchophylline (RIN) and Isorhynchophylline (IRN), a pair of isomeric alkaloids of Uncaria rhynchophylla (Miq.) Jacks. that has been used in China for centuries as a "cognitive enhancer" as well as to treat strokes. We further investigated whether RIN and IRN effectively suppress release of proinflammatory cytokines in LPS-activated microglial cells and the underling molecular mechanism for the inhibition of microglial activation. RIN and IRN concentration-dependently attenuated LPS-induced production of proinflammatory cytokines such as TNF-alpha and IL-1beta as well as NO in mouse N9 microglial cells, with IRN showing more potent inhibition of microglial activation. The western blotting analysis indicated that the potential molecular mechanism for RIN or IRN-mediated attenuation was implicated in suppressions of iNOS protein level, phosphorylation of ERK and p38 MAPKs, and degradation of IkappaBalpha. In addition, the differential regulation of the three signaling pathways by two isomers was shown. Our results suggest that RIN and IRN may be effective therapeutic candidates for use in the treatment of neurodegenerative diseases accompanied by microglial activation.